R
Richard James Booth Ellis
Researcher at Walton Centre
Publications - 9
Citations - 1114
Richard James Booth Ellis is an academic researcher from Walton Centre. The author has contributed to research in topics: Mitoxantrone & Cancer. The author has an hindex of 3, co-authored 9 publications receiving 727 citations.
Papers
More filters
Journal ArticleDOI
Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study.
Aravinthan Varatharaj,Aravinthan Varatharaj,Naomi Thomas,Mark Ellul,Mark Ellul,Mark Ellul,Nicholas W. S. Davies,Thomas A Pollak,Elizabeth L Tenorio,Mustafa Sultan,Ava Easton,Gerome Breen,Michael S. Zandi,Jonathan P. Coles,Hadi Manji,Rustam Al-Shahi Salman,David K. Menon,Timothy R Nicholson,Laura A Benjamin,Laura A Benjamin,Alan Carson,Craig J. Smith,Martin R Turner,Tom Solomon,Tom Solomon,Tom Solomon,Rachel Kneen,Rachel Kneen,Sarah Pett,Ian Galea,Ian Galea,Rhys H. Thomas,Rhys H. Thomas,Benedict D Michael,Benedict D Michael,Benedict D Michael,Claire Allen,Neil Archibald,James Arkell,Peter Arthur-Farraj,Mark R. Baker,Harriet A. Ball,Verity Bradley-Barker,Zoe Brown,Stefania Bruno,Lois Carey,Christopher Carswell,Annie Chakrabarti,James Choulerton,Mazen Daher,Ruth Davies,Rafael Di Marco Barros,Sofia Dima,Rachel Dunley,Dipankar Dutta,Richard James Booth Ellis,Alex Everitt,Joseph Fady,Patricia Fearon,Leonora Fisniku,Ivie Gbinigie,Alan Gemski,Emma Gillies,Effrossyni Gkrania-Klotsas,Julie Grigg,Hisham Hamdalla,Jack Hubbett,Neil Hunter,Anne-Catherine Huys,Ihmoda Ihmoda,Sissi Ispoglou,Ashwani Jha,Ramzi Joussi,Dheeraj Kalladka,Hind Khalifeh,Sander Kooij,Guru Kumar,Sandar Kyaw,Lucia Li,Edward Littleton,Malcolm R. Macleod,Mary Joan MacLeod,Barbara Madigan,Vikram Mahadasa,Manonmani Manoharan,Richard Marigold,Isaac Marks,Paul M. Matthews,Michael Mccormick,Caroline Mcinnes,Antonio Metastasio,Philip Milburn-McNulty,Clinton Mitchell,Duncan Mitchell,Clare Morgans,Huw R. Morris,Jasper M. Morrow,Ahmed Mubarak Mohamed,Paula Mulvenna,Louis Murphy,Robert Namushi,Edward J Newman,Wendy Phillips,Ashwin Pinto,David A Price,Harald Proschel,Terry Quinn,Deborah Ramsey,Christine Roffe,Amy L Ross Russell,Neshika Samarasekera,Stephen Sawcer,Walee Sayed,Lakshmanan Sekaran,Jordi Serra-Mestres,Victoria K. Snowdon,Gayle Strike,James Sun,Christina Tang,Mark Vrana,Ryckie G. Wade,Chris Wharton,Lou Wiblin,Iryna Boubriak,Katie Herman,Gordon T. Plant +125 more
TL;DR: This is the first nationwide, cross-specialty surveillance study of acute neurological and psychiatric complications of COVID-19 and provides valuable and timely data that are urgently needed by clinicians, researchers, and funders.
Journal ArticleDOI
Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?
TL;DR: Over 80% of cases occurred in patients exposed to >60 mg/m2, with a relative risk of 1.44 (CI95%:1.18–1.70) when comparing total dose >60 dosage against <60 dose strongly suggesting a relationship between risk of TRAL and total dose.
Journal ArticleDOI
Therapy-related acute leukaemia with mitoxantrone: Four years on, what is the risk and can it be limited?
TL;DR: MS treatment regimens which limit the mitoxantrone dose to < 60mg/m2 reduce the risk of TRAL, strongly suggesting a relationship to dose.
Journal ArticleDOI
Thalamic versus midbrain tremor; two distinct types of Holmes' Tremor: a review of 17 cases
N Nsengiyumva,N Nsengiyumva,A Barakat,Antonella Macerollo,Richard Pullicino,A Bleakley,Michael Bonello,Richard James Booth Ellis,Sundus Alusi +8 more
TL;DR: In this paper, the authors studied the clinical features and their radiological correlations to distinguish midbrain Holmes Tremor (HT) from thalamic HT (HT-t) from a retrospective review of 17 patients with a HT-type presentation.
Journal ArticleDOI
Therapy related acute leukaemia with mitoxantrone: 4 years on, what is the risk and can it be limited?
TL;DR: The current review suggests an incidence of TRAL following Mitoxantrone of 1 in 139, significantly higher than the previous analysis of all available data in 2008, and highlights that treatment regimes which limit the cumulative dose to <60 mg/m2 will minimise the risk of late leukaemia.